The best indicator for Novo Nordisk
We backtested 382 indicators across daily, weekly and hourly charts on real Novo Nordisk history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
EMA 13/48 Cross
On the weekly chart, this is the strongest risk-adjusted edge we found for Novo Nordisk over ~45.3 years — beating buy-and-hold by 1.1% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | EMA 13/48 Cross ✓ | Weekly | 16.1% | 0.78 | -34.3% | 73.3% | 15 | 1.1% |
| 2 | WMA 15/60 Cross ✓ | Weekly | 15.7% | 0.78 | -36.9% | 80.0% | 20 | 0.7% |
| 3 | SMA 50/200 Cross ✓ | Daily | 15.4% | 0.76 | -39.9% | 64.0% | 25 | 0.3% |
| 4 | T3 10/40 Cross ✓ | Weekly | 14.0% | 0.76 | -31.5% | 75.0% | 20 | -1.0% |
| 5 | WMA 10/40 Cross ✓ | Weekly | 14.8% | 0.75 | -38.1% | 52.9% | 34 | -0.2% |
| 6 | WMA 20/50 Cross ✓ | Weekly | 14.7% | 0.74 | -38.6% | 61.5% | 26 | -0.3% |
| 7 | WMA 20/80 Cross ✓ | Weekly | 14.8% | 0.74 | -43.4% | 68.8% | 16 | -0.2% |
| 8 | TRIX (15) ✓ | Weekly | 14.8% | 0.74 | -52.1% | 70.0% | 20 | -0.2% |
| 9 | Awesome Oscillator ✓ | Weekly | 14.3% | 0.73 | -39.3% | 53.8% | 39 | -0.6% |
| 10 | Guppy Multiple MA ✓ | Weekly | 14.9% | 0.73 | -43.0% | 69.6% | 23 | -0.1% |
| 11 | EMA 9/26 Cross ✓ | Weekly | 14.6% | 0.73 | -38.5% | 57.6% | 33 | -0.4% |
| 12 | SMA 10/40 Cross ✓ | Weekly | 14.3% | 0.73 | -47.7% | 61.5% | 26 | -0.7% |
| 13 | EMA 50/200 Cross ✓ | Daily | 14.9% | 0.72 | -45.2% | 61.9% | 21 | -0.2% |
| 14 | SMA 15/60 Cross ✓ | Weekly | 14.5% | 0.72 | -39.3% | 76.5% | 17 | -0.4% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Novo Nordisk, EMA 13/48 Cross on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.